Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTRBNASDAQ:NXLNASDAQ:VANINASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTRBNutriband$8.02+1.9%$6.67$3.72▼$11.78$87.78M1.1480,652 shs24,152 shsNXLNexalin Technology$0.99+0.2%$1.28$0.59▼$4.49$16.97M3.71597,461 shs24,744 shsVANIVivani Medical$1.26-2.3%$1.13$0.91▼$1.50$76.43M2.89100,076 shs75,946 shsZYXIZynex$2.66+3.1%$2.28$1.66▼$10.62$78.02M0.83172,841 shs125,258 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTRBNutriband+1.91%+2.82%+28.94%+38.99%+33.89%NXLNexalin Technology+0.22%-6.60%-17.44%-50.75%-40.36%VANIVivani Medical-2.33%-0.79%+1.59%+24.75%+0.80%ZYXIZynex+3.10%+6.40%+16.16%+9.02%-70.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNTRBNutriband3.2132 of 5 stars3.55.00.00.02.01.70.6NXLNexalin Technology2.6124 of 5 stars3.53.00.00.03.31.70.0VANIVivani Medical3.3031 of 5 stars3.55.00.00.01.93.30.0ZYXIZynex2.5962 of 5 stars3.21.00.00.02.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTRBNutriband 3.00Buy$13.0062.09% UpsideNXLNexalin Technology 3.00Buy$5.00405.05% UpsideVANIVivani Medical 3.00Buy$4.00217.46% UpsideZYXIZynex 2.33Hold$6.00125.56% UpsideCurrent Analyst Ratings BreakdownLatest NXL, NTRB, ZYXI, and VANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/19/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/30/2025ZYXIZynexRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.004/30/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.004/16/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/15/2025ZYXIZynexRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform4/4/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTRBNutriband$2.14M41.79N/AN/A$0.46 per share17.43NXLNexalin Technology$170K100.05N/AN/A$0.28 per share3.54VANIVivani MedicalN/AN/AN/AN/A$0.30 per shareN/AZYXIZynex$192.35M0.42$0.25 per share10.57$1.12 per share2.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/2/2025 (Estimated)NXLNexalin Technology-$7.61M-$0.83N/A∞N/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)VANIVivani Medical-$23.49M-$0.43N/AN/AN/AN/A-133.07%-56.50%8/12/2025 (Estimated)ZYXIZynex$2.99M-$0.24N/A5.66N/A-4.30%-23.70%-6.23%7/23/2025 (Estimated)Latest NXL, NTRB, ZYXI, and VANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2025Q2 2025ZYXIZynex-$0.20N/AN/AN/A$27.38 millionN/A5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 million5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million5/13/2025Q1 2025VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A4/28/2025Q4 2025NTRBNutriband-$0.12-$0.18-$0.06-$0.51$0.71 million$0.64 million4/28/2025Q1 2025ZYXIZynex-$0.24-$0.33-$0.09-$0.33$30.83 million$26.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNTRBNutribandN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTRBNutriband0.013.713.48NXLNexalin TechnologyN/A4.564.25VANIVivani MedicalN/A2.402.40ZYXIZynex2.873.462.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTRBNutriband19.70%NXLNexalin Technology0.65%VANIVivani Medical6.78%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipNTRBNutriband54.09%NXLNexalin Technology25.26%VANIVivani Medical46.40%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableNXLNexalin Technology317.18 million12.84 millionNot OptionableVANIVivani Medical2059.24 million31.76 millionOptionableZYXIZynex77030.24 million15.34 millionOptionableNXL, NTRB, ZYXI, and VANI HeadlinesRecent News About These CompaniesZynex (NASDAQ:ZYXI) Receives Buy Rating from HC WainwrightJuly 2 at 2:23 AM | americanbankingnews.comZynex appoints Steven Dyson as new CEOJune 30 at 12:24 PM | msn.comZynex's (ZYXI) Buy Rating Reaffirmed at HC WainwrightJune 30 at 10:47 AM | marketbeat.comZynex taps Steve Dyson as chief executive officerJune 30 at 10:17 AM | proactiveinvestors.comZynex Announces Steven Dyson as New CEOJune 30 at 9:15 AM | prnewswire.comZynex awarded UK patent for non-invasive sepsis monitoring technologyJune 25, 2025 | proactiveinvestors.comZynex Announces Award of UK Patent for Non-Invasive Detection of SepsisJune 25, 2025 | prnewswire.comZynex Announces Workforce ReductionJune 24, 2025 | marketwatch.comHere’s Why Zynex (ZYXI) Fell in Q1May 23, 2025 | msn.comZYXI DEADLINE ALERT: Zynex (ZYXI) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action – Hagens BermanMay 21, 2025 | morningstar.comMFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ZynexMay 21, 2025 | tmcnet.comZynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 ...May 19, 2025 | gurufocus.comLost Money on Zynex, Inc. (ZYXI)? Contact Levi & Korsinsky Before May 19, 2025 to Join Class ActionMay 19, 2025 | accessnewswire.comAZynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 Deadline to file Lead Plaintiff MotionMay 19, 2025 | globenewswire.comZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud LawsuitMay 19, 2025 | prnewswire.comZYXI Investors Have Opportunity to Lead Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI LAWSUIT ALERT: Levi & Korsinsky Notifies Zynex, Inc. Investors - Lead Plaintiff Deadline May 19, 2025May 19, 2025 | accessnewswire.comAZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 19, 2025 | businesswire.comZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXL, NTRB, ZYXI, and VANI Company DescriptionsNutriband NASDAQ:NTRB$8.02 +0.15 (+1.91%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$8.90 +0.89 (+11.03%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Nexalin Technology NASDAQ:NXL$0.99 +0.00 (+0.22%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$1.01 +0.02 (+1.62%) As of 08:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.Vivani Medical NASDAQ:VANI$1.26 -0.03 (-2.33%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$1.27 +0.01 (+1.19%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Zynex NASDAQ:ZYXI$2.66 +0.08 (+3.10%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$2.66 +0.00 (+0.19%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
